ArticleFrontiers in immunology2023

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.

Qi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.